Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03761563 · ClinicalTrials.gov registry record
Clinical Evaluation of Fortilink® TETRAfuse® Interbody Fusion Device in Subjects With Degenerative Disc Disease
A clinical trial, sponsored by Xtant Medical.
- Completed
- Registry status
- 15
- Enrollment target
NCT03761563: Completed study, sponsored by Xtant Medical.
NCT03761563 is a clinical trial that has completed, run by Xtant Medical. The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03761563 has completed, sponsored by Xtant Medical.
- COMPLETED
- Registry status
- 15 participants
- Enrollment target
Study Summary
This is a prospective, multi-center, non-randomized post-market evaluation designed to collect and evaluate data on the safety and performance of the Fortilink IBF System with TETRAfuse 3D Technology.
Interventions
- DEVICE Fortilink IBF System with TETRAfuse Technology
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2019-02-13 |
| Est. Completion | 2023-12-30 |
What the finished NCT03761563 record still lists
NCT03761563 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 15 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Fortilink IBF System with TETRAfuse Technology is the first listed.
NCT03761563 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03761563 about?
NCT03761563 is a clinical study titled "Clinical Evaluation of Fortilink® TETRAfuse® Interbody Fusion Device in Subjects With Degenerative Disc Disease". This is a prospective, multi-center, non-randomized post-market evaluation designed to collect and evaluate data on the safety and performance of the Fortilink IBF System with TETRAfuse 3D Technology.
What is the current status of trial NCT03761563?
This trial is currently completed. The enrollment target is 15 participants. The study started on 2019-02-13. Estimated completion is 2023-12-30.
What interventions are being tested in trial NCT03761563?
The interventions under investigation include: Fortilink IBF System with TETRAfuse Technology (DEVICE).
Who is sponsoring clinical trial NCT03761563?
This trial is sponsored by Xtant Medical, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI